Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells

Science Translational Medicine

Volumn 5, Issue 197, 2013, Pages

  Cameron, Brian J ^a   Gerry, Andrew B ^b   Dukes, Joseph ^a   Harper, Jane V ^a   Kannan, Vivekanandan ^a   Bianchi, Frayne C ^a   Grand, Francis ^a   Brewer, Joanna E ^b   Gupta, Minnal ^c   Plesa, Gabriela ^c   Bossi, Giovanna ^a   Vuidepot, Annelise ^a   Powlesland, Alex S ^a   Legg, Alison ^a   Adams, Katherine J ^b   Bennett, Alan D ^b   Pumphrey, Nicholas J ^b   Williams, Daniel D ^b   Binder Scholl, Gwendolyn ^b   Kulikovskaya, Irina ^c   Levine, Bruce L ^c   Riley, James L ^c   Varela Rohena, Angel ^c   Stadtmauer, Edward A ^c   Rapoport, Aaron P ^d   Linette, Gerald P ^e   June, Carl H ^c   Hassan, Namir J ^a   Kalos, Michael ^c   Jakobsen, Bent K ^a,b   more..

^a Immunocore Limited   (United Kingdom)

^b Adaptimmune Ltd   (United Kingdom)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIN; HLA A1 ANTIGEN; MELANOMA ANTIGEN 3; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CARDIOTOXICITY; CELL ENGINEERING; CONTROLLED STUDY; CROSS REACTION; FATALITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CONNECTIN; CROSS REACTIONS; HEK293 CELLS; HLA-A1 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; MYOCYTES, CARDIAC; NEOPLASM PROTEINS; PEPTIDES; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84883866836     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006034     Document Type: Article

References (47)

1. N. P. Restifo, M. E. Dudley, S. A. Rosenberg, Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat. Rev. Immunol. 12, 269-281 (2012).
2. R. A. Morgan, J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot, S. A. Rosenberg, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 . Mol. Ther. 18, 843-851 (2010).
3. M. R. Parkhurst, J. C. Yang, R. C. Langan, M. E. Dudley, D. A. Nathan, S. A. Feldman, J. L. Davis, R. A. Morgan, M. J. Merino, R. M. Sherry, M. S. Hughes, U. S. Kammula, G. Q. Phan, R. M. Lim, S. A. Wank, N. P. Restifo, P. F. Robbins, C. M. Laurencot, S. A. Rosenberg, T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620-626 (2011).
4. P. F. Robbins, R. A. Morgan, S. A. Feldman, J. C. Yang, R. M. Sherry, M. E. Dudley, J. R. Wunderlich, A. V. Nahvi, L. J. Helman, C. L. Mackall, U. S. Kammula, M. S. Hughes, N. P. Restifo, M. Raffeld, C. C. Lee, C. L. Levy, Y. F. Li, M. El-Gamil, S. L. Schwarz, C. Laurencot, S. A. Rosenberg, Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917-924 (2011).
5. M. Kalos, A. P. Rapoport, E. A. Stadtmauer, D. T. Vogl, B. M. Weiss, G. K. Binder-Scholl, D. P. Smethurst, I. Kulikovskaya, M. Gupta, T. L. Macatee, J. M. Finklestein, J. E. Brewer, A. D. Bennett, A. B. Gerry, N. J. Pumphrey, H. K. Tayton-Martin, E. Veloso, Z. Zheng, A. Z. Badros, S. Yanovich, G. Akpek, H. McConville, S. Philip, B. L. Levine, B. K. Jakobsen, C. H. June, Prolonged T cell persistence, homing to marrow and selective targeting of antigen positive tumor in multiple myeloma patients following adoptive transfer of T cells genetically engineered to express an affinityenhanced T cell receptor against the cancer testis antigens NY-ESO-1 and Lage-1. Blood (ASH Annu. Meet. Abstr.) 120, 755 (2012).
6. M. Aleksic, N. Liddy, P. E. Molloy, N. Pumphrey, A. Vuidepot, K. M. Chang, B. K. Jakobsen, Different affinity windows for virus and cancer-specific T-cell receptors: Implications for therapeutic strategies. Eur. J. Immunol. 42, 3174-3179 (2012).
7. T. C. Manning, E. A. Parke, L. Teyton, D. M. Kranz, Effects of complementarity determining region mutations on the affinity of an α/β T cell receptor: Measuring the energy associated with CD4/CD8 repertoire skewing. J. Exp. Med. 189, 461-470 (1999).
8. T. C. Manning, C. J. Schlueter, T. C. Brodnicki, E. A. Parke, J. A. Speir, K. C. Garcia, L. Teyton, I. A. Wilson, D. M. Kranz, Alanine scanning mutagenesis of an αβ T cell receptor: Mapping the energy of antigen recognition. Immunity 8, 413-425 (1998).
9. P. F. Robbins, Y. F. Li, M. El-Gamil, Y. Zhao, J. A. Wargo, Z. Zheng, H. Xu, R. A. Morgan, S. A. Feldman, L. A. Johnson, A. D. Bennett, S. M. Dunn, T. M. Mahon, B. K. Jakobsen, S. A. Rosenberg, Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180, 6116-6131 (2008).
10. P. D. Holler, L. K. Chlewicki, D. M. Kranz, TCRs with high affinity for foreign pMHC show selfreactivity. Nat. Immunol. 4, 55-62 (2003).
11. K. S. Weber, D. L. Donermeyer, P. M. Allen, D. M. Kranz, Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function. Proc. Natl. Acad. Sci. U.S.A. 102, 19033-19038 (2005).
12. Y. Li, R. Moysey, P. E. Molloy, A. L. Vuidepot, T. Mahon, E. Baston, S. Dunn, N. Liddy, J. Jacob, B. K. Jakobsen, J. M. Boulter, Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23, 349-354 (2005).
13. A. S. Chervin, D. H. Aggen, J. M. Raseman, D. M. Kranz, Engineering higher affinity T cell receptors using a T cell display system. J. Immunol. Methods 339, 175-184 (2008).
14. A. Varela-Rohena, C. Carpenito, E. E. Perez, M. Richardson, R. V. Parry, M. Milone, J. Scholler, X. Hao, A. Mexas, R. G. Carroll, C. H. June, J. L. Riley, Genetic engineering of T cells for adoptive immunotherapy. Immunol. Res. 42, 166-181 (2008).
15. M.M. van Loenen, R. de Boer, A. L. Amir, R. S. Hagedoorn, G. L. Volbeda, R. Willemze, J. J. van Rood, J. H. Falkenburg, M. H. Heemskerk, Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc. Natl. Acad. Sci. U.S.A. 107, 10972-10977 (2010).
16. S. M. Amos, C. P. Duong, J. A. Westwood, D. S. Ritchie, R. P. Junghans, P. K. Darcy, M. H. Kershaw, Autoimmunity associated with immunotherapy of cancer. Blood 118, 499-509 (2011).
17. L. A. Johnson, R. A. Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. Hughes, U. S. Kammula, R. E. Royal, R. M. Sherry, J. R. Wunderlich, C. C. Lee, N. P. Restifo, S. L. Schwarz, A. P. Cogdill, R. J. Bishop, H. Kim, C. C. Brewer, S. F. Rudy, C. Van Waes, J. L. Davis, A. Mathur, R. T. Ripley, D. A. Nathan, C. M. Laurencot, S. A. Rosenberg, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546 (2009).
18. O. L. Caballero, Y. T. Chen, Cancer/testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci. 100, 2014-2021 (2009).
19. B. Gaugler, B. Van den Eynde, P. van der Bruggen, P. Romero, J. J. Gaforio, E. De Plaen, B. Lethé, F. Brasseur, T. Boon, Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179, 921-930 (1994).
20. F. Brasseur, D. Rimoldi, D. Liénard, B. Lethé, S. Carrel, F. Arienti, L. Suter, R. Vanwijck, A. Bourlond, Y. Humblet, A. Vacca, M. Conese, T. Lahaye, G. Degiovanni, R. Deraemaecker, M. Beauduin, X. Sastre, E. Salamon, B. Dréno, E. Jäger, A. Knuth, C. Chevreau, S. Suciu, J.-M. Lachapelle, P. Pouillart, G. Parmiani, F. Lejeune, J.-C. Cerottini, T. Boon, M. Marchand, Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int. J. Cancer 63, 375-380 (1995).
21. J. J. Patard, F. Brasseur, S. Gil-Diez, F. Radvanyi, M. Marchand, P. François, A. Abi-Aad, P. Van Cangh, C. C. Abbou, D. Chopin, T. Boon, Expression of mage genes in transitional-cell carcinomas of the urinary bladder. Int. J. Cancer 64, 60-64 (1995).
22. P. van der Bruggen, C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, T. Boon, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647 (1991).
23. V. Karanikas, C. Lurquin, D. Colau, N. van Baren, C. De Smet, B. Lethé, T. Connerotte, V. Corbière, M. A. Demoitié, D. Liénard, B. Dréno, T. Velu, T. Boon, P. G. Coulie, Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J. Immunol. 171, 4898-4904 (2003).
24. M. Marchand, N. van Baren, P. Weynants, V. Brichard, B. Dréno, M. H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, A. Bourlond, R. Vanwijck, D. Liénard, M. Beauduin, P. Y. Dietrich, V. Russo, J. Kerger, G. Masucci, E. Jäger, J. DeGreve, J. Atzpodien, F. Brasseur, P.G. Coulie, P. van der Bruggen, T. Boon, Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80, 219-230 (1999).
25. J. Gotter, B. Brors, M. Hergenhahn, B. Kyewski, Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp. Med. 199, 155-166 (2004).
26. T. Connerotte, A. Van Pel, D. Godelaine, E. Tartour, B. Schuler-Thurner, S. Lucas, K. Thielemans, G. Schuler, P. G. Coulie, Functions of anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res. 68, 3931-3940 (2008).
27. G. P. Linette, E. A. Stadtmauer, M. V. Maus, A. P. Rapoport, B. L. Levine, L. Emery, L. Litzky, A. Bagg, B. M. Carreno, P. J. Cimino, G. K. Binder-Scholl, D. P. Smethurst, A. B. Gerry, N. J. Pumphrey, A. D. Bennett, J. E. Brewer, J. Dukes, J. Harper, H. K. Tayton-Martin, B. K. Jakobsen, N. J. Hassan, M. Kalos, C. H. June, Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma, Blood 10.1182/blood-2013-03-490565 (2013).
28. J. Ma, L. Guo, S. J. Fiene, B. D. Anson, J. A. Thomson, T. J. Kamp, K. L. Kolaja, B. J. Swanson, C. T. January, High purity human-induced pluripotent stem cell-derived cardiomyocytes: Electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 301, H2006-H2017 (2011).
29. R. A. Morgan, N. Chinnasamy, D. Abate-Daga, A. Gros, P. F. Robbins, Z. Zheng, M. E. Dudley, S. A. Feldman, J. C. Yang, R. M. Sherry, G. Q. Phan, M. S. Hughes, U. S. Kammula, A. D. Miller, C. J. Hessman, A. A. Stewart, N. P. Restifo, M. M. Quezado, M. Alimchandani, A. Z. Rosenberg, A. Nath, T. Wang, B. Bielekova, S. C. Wuest, N. Akula, F. J. McMahon, S. Wilde, B. Mosetter, D. J. Schendel, C. M. Laurencot, S. A. Rosenberg, Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133-151 (2013).
30. G. M. Bendle, C. Linnemann, A. I. Hooijkaas, L. Bies, M. A. de Witte, A. Jorritsma, A. D. Kaiser, N. Pouw, R. Debets, E. Kieback, W. Uckert, J. Y. Song, J. B. Haanen, T. N. Schumacher, Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16, 565-570 (2010).
31. S. A. Rosenberg, Of mice, not men: No evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol. Ther. 18, 1744-1745 (2010).
32. L. Wooldridge, J. Ekeruche-Makinde, H. A. van den Berg, A. Skowera, J. J. Miles, M. P. Tan, G. Dolton, M. Clement, S. Llewellyn-Lacey, D. A. Price, M. Peakman, A. K. Sewell, A single autoimmune T cell receptor recognizes more than a million different peptides. J. Biol. Chem. 287, 1168-1177 (2012).
33. F. T. Van der Loop, G. J. Van Eys, G. Schaart, F. C. Ramaekers, Titin expression as an early indication of heart and skeletal muscle differentiation in vitro. Developmental re-organisation in relation to cytoskeletal constituents. J. Muscle Res. Cell Motil. 17, 23-36 (1996).
34. C. Carpenito, M. C. Milone, R. Hassan, J. C. Simonet, M. Lakhal, M. M. Suhoski, A. Varela-Rohena, K.M. Haines, D. F. Heitjan, S. M. Albelda, R. G. Carroll, J. L. Riley, I. Pastan, C. H. June, Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. U.S.A. 106, 3360-3365 (2009).
35. C. C. Bertozzi, C. Y. Chang, S. Jairaj, X. Shan, J. Huang, B. L. Weber, C. S. Chu, R. G. Carroll, Multiple initial culture conditions enhance the establishment of cell lines from primary ovarian cancer specimens. In Vitro Cell. Dev. Biol. Anim. 42, 58-62 (2006).
36. R. V. Parry, C. A. Rumbley, L. H. Vandenberghe, C. H. June, J. L. Riley, CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J. Immunol. 171, 166-174 (2003).
37. T. Dull, R. Zufferey, M. Kelly, R. J. Mandel, M. Nguyen, D. Trono, L. Naldini, A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471 (1998).
38. J. M. Boulter, M. Glick, P. T. Todorov, E. Baston, M. Sami, P. Rizkallah, B. K. Jakobsen, Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng. 16, 707-711 (2003).
39. D. N. Garboczi, D. T. Hung, D. C. Wiley, HLA-A2-peptide complexes: Refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc. Natl. Acad. Sci. U.S.A. 89, 3429-3433 (1992).
40. C. A. O'callaghan, M. F. Byford, J. R. Wyer, B. E. Willcox, B. K. Jakobsen, A. J. McMichael, J. I. Bell, BirA enzyme: Production and application in the study of membrane receptor-ligand interactions by site-specific biotinylation. Anal. Biochem. 266, 9-15 (1999).
41. N. Liddy, G. Bossi, K. J. Adams, A. Lissina, T. M. Mahon, N. J. Hassan, J. Gavarret, F. C. Bianchi, N. J. Pumphrey, K. Ladell, E. Gostick, A. K. Sewell, N. M. Lissin, N. E. Harwood, P. E. Molloy, Y. Li, B. J. Cameron, M. Sami, E. E. Baston, P. T. Todorov, S. J. Paston, R. E. Dennis, J. V. Harper, S. M. Dunn, R. Ashfield, A. Johnson, Y. McGrath, G. Plesa, C. H. June, M. Kalos, D. A. Price, A. Vuidepot, D. D. Williams, D. H. Sutton, B. K. Jakobsen, Monoclonal TCR-redirected tumor cell killing. Nat. Med. 8, 980-987 (2012).
42. E. McCormack, K. J. Adams, N. J. Hassan, A. Kotian, N. M. Lissin, M. Sami, M. Mujić, T. Osdal, B. T. Gjertsen, D. Baker, A. S. Powlesland, M. Aleksic, A. Vuidepot, O. Morteau, D. H. Sutton, C.H. June, M. Kalos, R. Ashfield, B. K. Jakobsen, Bi-specificTCR-anti CD3redirectedT-cell targeting of NY-ESO-1-and LAGE-1-positive tumors. Cancer Immunol. Immunother. 62, 773-785 (2012).
43. S. F. Altschul, T. L. Madden, A. A. Schäffer, J. Zhang, Z. Zhang, W. Miller, D. J. Lipman, Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res. 25, 3389-3402 (1997).
44. W. J. Storkus, H. J. Zeh III, R. D. Salter, M. T. Lotze, Identification of T-cell epitopes: Rapid isolation of class I-presented peptides from viable cells by mild acid elution. J. Immunother. Emphasis Tumor Immunol. 14, 94-103 (1993).
45. M. W. Pfaffl, A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).
46. M. R. Du, W. H. Zhou, F. T. Yan, X. Y. Zhu, Y. Y. He, J. Y. Yang, D. J. Li, Cyclosporine A induces titin expression via MAPK/ERK signalling and improves proliferative and invasive potential of human trophoblast cells. Hum. Reprod. 22, 2528-2537 (2007).
47. B. J. Cameron, A. B. Gerry, J. Dukes, J. V. Harper, V. Kannan, F. C. Bianchi, F. Grand, J. E. Brewer, M. Gupta, G. Plesa, G. Bossi, A. Vuidepot, A. S. Powlesland, A. Legg, K. J. Adams, A. D. Bennett, N. J. Pumphrey, D. D. Williams, G. Binder-Scholl, I. Kulikovskaya, B. L. Levine, J. L. Riley, A. Varela-Rohena, E. A. Stadtmauer, A. P. Rapoport, G. P. Linette, C. H. June, N. J. Hassan, M. Kalos, B. K. Jakobsen, Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197ra103 (2013)